Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by TCG Crossover Management LLC

TCG Crossover Management LLC lessened its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 37.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 550,000 shares of the company’s stock after selling 329,344 shares during the period. TCG Crossover Management LLC’s holdings in Keros Therapeutics were worth $8,706,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of KROS. Lynx1 Capital Management LP acquired a new position in Keros Therapeutics in the fourth quarter worth about $8,612,000. Walleye Capital LLC bought a new stake in shares of Keros Therapeutics in the 4th quarter valued at approximately $3,129,000. Clearbridge Investments LLC acquired a new stake in shares of Keros Therapeutics during the 4th quarter valued at approximately $3,009,000. JPMorgan Chase & Co. lifted its stake in Keros Therapeutics by 585.9% during the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company’s stock worth $3,379,000 after purchasing an additional 182,314 shares during the last quarter. Finally, Darwin Global Management Ltd. boosted its holdings in Keros Therapeutics by 10.7% in the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock worth $26,707,000 after purchasing an additional 163,403 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KROS has been the topic of a number of recent research reports. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Truist Financial reduced their price objective on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Finally, Piper Sandler reduced their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Keros Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction dated Wednesday, April 9th. The shares were bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.90% of the stock is owned by corporate insiders.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $14.26 on Tuesday. The stock’s 50 day moving average price is $11.63 and its 200 day moving average price is $27.13. The stock has a market cap of $579.11 million, a price-to-earnings ratio of -2.74 and a beta of 1.39. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. On average, sell-side analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.